サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1212750

治療薬モニタリングの世界市場：製品別 (消耗品、装置 (イムノアッセイ分析装置、クロマトグラフィー・MS検出器、臨床化学分析装置))・技術別・薬剤クラス別・エンドユーザー別・地域別の将来予測 (2027年まで)

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2027
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 214 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
治療薬モニタリングの世界市場：製品別 (消耗品、装置 (イムノアッセイ分析装置、クロマトグラフィー・MS検出器、臨床化学分析装置))・技術別・薬剤クラス別・エンドユーザー別・地域別の将来予測 (2027年まで)
出版日: 2023年02月01日
発行: MarketsandMarkets
ページ情報: 英文 214 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の治療薬モニタリングの市場規模は、2022年の18億米ドルから2027年には29億米ドルに達すると予測され、予測期間中に9.6%のCAGRで成長する見通しです。

市場成長の主な促進要因として、臓器移植手術の待望論が高いことと、精密医療への傾倒が拡大していることが主な要因です。しかし、中低所得国でのインフラの欠如や認知度の低さが、この市場の成長を阻む可能性があります。

技術別では、液体クロマトグラフィー・質量分析 (LC-MS) 装置が予測期間中に最も高く成長する見通しです。TDM薬剤の手頃な価格や信頼性、自動化プラットフォームでの利用可能性、高度なHPLCの利用、といった幅広い利点が市場成長の促進材料となっています。

地域別に見ると、アジア太平洋が予測期間中に最も高いCAGRで成長すると推定されます。その主な要因として、主に人口の増加 (特に日本と中国)、日本における包括的な政府医療保険の利用可能性 (移植および関連診断処置)、原疾患の検出と健康診断に関する意識を高める政府の取り組み、医療インフラの改造と拡大のための中国とインドの政府支出の増加、重症疾患の蔓延が原因などが挙げられます。

当レポートでは、世界の治療薬モニタリングの市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、製品別・技術別・薬剤クラス別・エンドユーザー別・地域別の市場動向の見通し、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 技術分析
  • バリューチェーン分析
  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • 主な利害関係者と購入基準
  • 規制状況
  • 主な会議とイベント (2022年・2023年)
  • 特許分析
  • 価格分析
  • 貿易分析
  • エコシステム分析
  • 顧客のビジネスに影響を与える動向/混乱

第6章 治療薬モニタリング市場：製品別

  • イントロダクション
  • 消耗品
  • 装置
    • イムノアッセイ分析装置
    • クロマトグラフィー・MS検出器
    • 臨床化学分析装置

第7章 治療薬モニタリング市場：技術別

  • イントロダクション
  • イムノアッセイ (免疫測定)
    • 化学発光イムノアッセイ
    • 蛍光イムノアッセイ
    • 比色イムノアッセイ
    • 放射免疫測定 (ラジオイムノアッセイ)
    • その他のイムノアッセイ
  • クロマトグラフィー・質量分析 (MS)
    • 液体クロマトグラフィー・質量分析 (LC-MS)
    • ガスクロマトグラフィー・質量分析 (GC-MS)

第8章 治療薬モニタリング市場：薬剤クラス別

  • イントロダクション
  • 抗てんかん薬
  • 抗不整脈薬
  • 免疫抑制剤
  • 抗生物質
  • 気管支拡張薬
  • 向精神薬
  • その他の薬剤

第9章 治療薬モニタリング市場：エンドユーザー別

  • イントロダクション
  • 病院検査室
  • 商業・民間検査室
  • その他のエンドユーザー

第10章 治療薬モニタリング市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • 英国
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 他のアジア太平洋諸国
  • 他の国々 (RoW)

第11章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価クアドラント
  • 中小企業/新興企業向けの企業評価クアドラント
  • 企業のフットプリント分析
  • 治療薬モニタリング市場：主要なスタートアップ/中小企業の一覧
  • 競合シナリオ
    • 製品の発売と承認
    • 資本取引
    • その他の動向

第12章 企業プロファイル

  • 主要企業
    • ABBOTT
    • THERMO FISHER SCIENTIFIC
    • F. HOFFMANN-LA ROCHE
    • SIEMENS HEALTHINEERS AG
    • DANAHER CORPORATION
    • BIO-RAD LABORATORIES
    • BIOMERIEUX SA
    • THERADIAG
    • GRIFOLS S.A.
    • EXAGEN INC.
    • ARK DIAGNOSTICS, INC.
    • R-BIOPHARM AG
  • その他の企業
    • APDIA GROUP
    • BIOTEZ BERLIN BUCH GMBH
    • EAGLE BIOSCIENCES, INC.
    • JASEM LABORATORY SYSTEMS AND SOLUTIONS
    • AALTO SCIENTIFIC, LTD.
    • IMMUNDIAGNOSTIK AG
    • UTAK
    • SEKISUI MEDICAL CO., LTD.
    • DIASYSTEM SCANDINAVIA AB
    • CAMBRIDGE LIFE SCIENCES LIMITED
    • CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
    • BUHLMANN LABORATORIES AG
    • SJK GLOBAL, LLC.
    • EPITOPE DIAGNOSTICS, INC.

第13章 付録

目次
Product Code: MD 4185

The global therapeutic drug monitoring market is projected to reach USD 2.9 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 9.6% during the forecast period. The growth of this market is majorly driven by a high awaiting number of organ transplant procedures and the expanding inclination for precision medicine. However, a lack of infrastructure and low awareness in middle/low-income countries may challenge the growth of this market.

"Liquid Chromatography-Mass Spectrometry in the technology segment to witness the highest growth during the forecast period."

Based on the technology, the Therapeutic Drug Monitoring Market is segmented into Immunoassays - Chemiluminescence Immunoassays, Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, Radioimmunoassay, Other Immunoassays, Chromatography-MS - LC-MS, GC-MS, The LC-MS is projected to grow at the highest CAGR during the forecast period. The significant factors contributing to the growth of this market are affordability, reliability, and its availability in automated platform, as well as wide benefits of advanced HPLC usage in TDM drugs.

"Asia Pacific is estimated to register the highest CAGR during the forecast period."

In this report, the Therapeutic Drug Monitoring market is segmented into four major regional segments: North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the upsurging population (especially in Japan and China), availaibility of comprehensive government healthcare coverage in Japan (for transplantation & related diagnostic procedures), government efforts to increase awareness about primitive disease detection and health check-ups, rising government expenditure in China and India to remodel and expand healthcare infrastructure, and the growing prevalence of severe diseases

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
  • By Designation: C-level (30%), Director-level (34%), and Others (36%)
  • By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)

List of Companies Profiled in the Report

  • Abbott (US)
  • Thermo Fisher Scientific (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Siemens Healthineers AG (Germany)
  • Danaher Corporation (US)
  • Bio-Rad Laboratories (US)
  • bioMerieux SA (France)
  • Theradiag SA (France)
  • Grifols S.A. (Spain)
  • Exagen Inc. (US)
  • R-Biopharm AG (Germany)
  • ARK DIAGNOSTICS, Inc. (US)
  • Cambridge Life Sciences Limited (UK)
  • BUHLMANN Laboratories (Switzerland)
  • IMMUNDIAGNOSTIK AG (Germany)
  • BioTeZ Berlin-Buch GmbH (Germany)
  • UTAK (US)
  • DiaSystem Scandinavia AB (Sweden)
  • Jasem Laboratory Systems and Solutions (Turkey)
  • Aalto Scientific, Ltd. (US)
  • apDia Group (Belgium)
  • SJK Global, LLC. (US)
  • Epitope Diagnostics, Inc. (US)
  • Sekisui Medical Co. Ltd. (Japan)
  • Eagle Biosciences, Inc. (US)
  • Chromsystems Instruments & Chemicals GmbH (Germany)

Research Coverage:

This report studies the Therapeutic Drug Monitoring market based on product and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Therapeutic Drug Monitoring market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on Therapeutic Drug Monitoring products offered by the top 26 players in the therapeutic drug monitoring market. The report analyzes the therapeutic drug monitoring market by product, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Therapeutic Drug Monitoring market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Therapeutic Drug Monitoring market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
    • TABLE 1 KEY DATA FROM PRIMARY SOURCES
    • FIGURE 3 KEY INDUSTRY INSIGHTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
    • FIGURE 7 APPROACH 3: MARKET SIZE ESTIMATION FROM PARENT MARKET
      • 2.2.1.1 Growth forecast
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 9 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 IMPACT OF RECESSION

3 EXECUTIVE SUMMARY

    • FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 GEOGRAPHIC ANALYSIS: THERAPEUTIC DRUG MONITORING MARKET

4 PREMIUM INSIGHTS

  • 4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
    • FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE TDM MARKET
  • 4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY AND DRUG CLASS
    • FIGURE 17 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE IN 2021
  • 4.3 THERAPEUTIC DRUG MONITORING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 CHINA TO REGISTER HIGHEST CAGR
  • 4.4 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (2022-2027)
    • FIGURE 19 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPED VS. EMERGING ECONOMIES
    • FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Importance of TDM in organ transplant procedures
    • FIGURE 22 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS (APRIL 1, 2017-MARCH 31, 2021)
      • 5.2.1.2 Use of TDM across various therapeutic fields
    • TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
      • 5.2.1.3 Increasing preference for precision medicine
    • FIGURE 23 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015-2021
      • 5.2.1.4 Growing focus on R&D related to TDM
    • FIGURE 24 NUMBER OF RESEARCH PUBLICATIONS ON TDM (2015-2021)
      • 5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
    • FIGURE 25 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
    • TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments
      • 5.2.2.2 Reluctance of small hospitals to offer TDM services
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing prevalence of autoimmune diseases
      • 5.2.3.2 Significant opportunities in BRICS countries
    • FIGURE 26 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012-2019
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Alternatives to conventional TDM
      • 5.2.4.2 Operational barriers faced in conducting TDM tests
      • 5.2.4.3 Lack of infrastructure and low awareness in low/middle-income countries
  • 5.3 TECHNOLOGY ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 28 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 THREAT OF SUBSTITUTES
  • 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
    • TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
    • 5.7.2 BUYING CRITERIA
    • FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS
    • TABLE 5 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • 5.8 REGULATORY LANDSCAPE
    • TABLE 6 REGULATORY AUTHORITIES GOVERNING TDM MARKET
  • 5.9 KEY CONFERENCES AND EVENTS IN 2022 AND 2023
    • TABLE 7 LIST OF CONFERENCES AND EVENTS, 2022-2023
  • 5.10 PATENT ANALYSIS
    • FIGURE 31 PATENT ANALYSIS FOR IMMUNOASSAY ANALYZERS
    • FIGURE 32 PATENT ANALYSIS FOR CLINICAL CHEMISTRY ANALYZERS
  • 5.11 PRICING ANALYSIS
    • TABLE 8 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
    • TABLE 9 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING PRODUCTS
  • 5.12 TRADE ANALYSIS
    • TABLE 10 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016-2021 (USD MILLION)
    • TABLE 11 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016-2021 (USD MILLION)
  • 5.13 ECOSYSTEM ANALYSIS
    • TABLE 12 ROLE IN ECOSYSTEM
    • FIGURE 33 KEY MARKET PLAYERS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
    • FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 13 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
  • 6.2 CONSUMABLES
    • 6.2.1 REPEAT PURCHASES AND HIGH USAGE OF CONSUMABLES TO DRIVE MARKET
    • TABLE 14 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 EQUIPMENT
    • TABLE 15 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
    • TABLE 16 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 17 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.1 IMMUNOASSAY ANALYZERS
      • 6.3.1.1 High efficiency of immunoassay analyzers to ensure end-user demand
    • TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 CHROMATOGRAPHY & MS DETECTORS
      • 6.3.2.1 Technological advancements to propel growth
    • TABLE 19 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY (2020 TO 2021)
    • TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.3 CLINICAL CHEMISTRY ANALYZERS
      • 6.3.3.1 Automation to raise preference for clinical chemistry analyzers
    • TABLE 21 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020-2027 (USD MILLION)

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 IMMUNOASSAYS
    • TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS
      • 7.2.1.1 Rapid detection time and good specificity to support growth
    • TABLE 25 CLIA SYSTEMS OFFERED, BY COMPANY
    • TABLE 26 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
    • TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.2 FLUORESCENCE IMMUNOASSAYS
      • 7.2.2.1 High operability and better sensitivity of FIAs to drive market growth
    • TABLE 28 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
    • TABLE 29 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.3 COLORIMETRIC IMMUNOASSAYS
      • 7.2.3.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
    • TABLE 30 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.4 RADIOIMMUNOASSAYS
      • 7.2.4.1 High sensitivity in drug detection applications to support market growth
    • TABLE 31 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS
    • TABLE 32 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.5 OTHER IMMUNOASSAYS
    • TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 CHROMATOGRAPHY-MS
    • TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • 7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
      • 7.3.1.1 High accuracy to drive demand for LC-MS
    • TABLE 35 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
      • 7.3.2.1 Drawbacks of GC-MS to challenge market growth
    • TABLE 36 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020-2027 (USD MILLION)

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

  • 8.1 INTRODUCTION
    • TABLE 37 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
  • 8.2 ANTIEPILEPTIC DRUGS
    • 8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
    • TABLE 38 TDM: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
    • TABLE 39 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 ANTIARRHYTHMIC DRUGS
    • 8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
    • TABLE 40 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.4 IMMUNOSUPPRESSANT DRUGS
    • 8.4.1 RISING IMMUNOSUPPRESSANT DEMAND DRIVEN BY INCREASE IN ORGAN TRANSPLANTATION PROCEDURES
    • FIGURE 35 PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2021
    • TABLE 41 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 ANTIBIOTIC DRUGS
    • 8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND FOR ANTIBIOTIC DRUG MONITORING
    • TABLE 42 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIALS LEVELS IN BIOFLUIDS
    • TABLE 43 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.6 BRONCHODILATOR DRUGS
    • 8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
    • TABLE 44 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.7 PSYCHOACTIVE DRUGS
    • 8.7.1 SURGING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
    • TABLE 45 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.8 OTHER DRUGS
    • TABLE 46 OTHER DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)

9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 HOSPITAL LABORATORIES
    • 9.2.1 HOSPITAL LABS TO DOMINATE END-USER MARKET
    • TABLE 48 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 COMMERCIAL & PRIVATE LABORATORIES
    • 9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
    • TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 OTHER END USERS
    • TABLE 50 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 51 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
    • TABLE 52 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 54 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 58 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 59 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Awareness regarding precision medicine to propel market
    • TABLE 60 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
    • TABLE 61 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 62 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 63 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 66 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Availability of funding for research to offer growth opportunities
    • TABLE 67 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 68 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 69 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 70 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 72 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 73 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 74 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 77 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 78 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 80 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Prevalence of chronic medical conditions such as cancer and diabetes to support market growth
    • TABLE 81 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 82 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 83 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 85 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 86 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.3 ITALY
      • 10.3.3.1 Rising incidence of cancer to drive demand for TDM
    • TABLE 87 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
    • TABLE 88 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 89 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 90 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 91 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 92 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 93 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising awareness of benefits of TDM to accelerate demand
    • TABLE 94 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 95 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 96 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 98 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 99 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Adoption of technologically advanced immunoassays to boost market
    • TABLE 100 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
    • TABLE 101 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 102 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 103 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 104 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 106 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.6 UK
      • 10.3.6.1 Increasing cases of chronic diseases to support market
    • TABLE 107 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 108 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 109 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 110 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 111 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 112 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 113 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 114 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 115 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 116 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 118 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 37 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
    • TABLE 119 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY- MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Japan to dominate APAC market
    • TABLE 127 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
    • TABLE 128 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 129 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 130 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 131 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 132 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 133 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Rising number of organ transplants to boost market
    • TABLE 134 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 135 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 136 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 137 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 138 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 139 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Rising incidence of cancer to propel market
    • TABLE 140 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 141 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 142 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 143 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 144 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 145 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.5 ROAPAC
    • TABLE 146 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 147 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 148 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 149 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 150 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 151 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • 10.5.1 ROW: RECESSION IMPACT
    • TABLE 152 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 153 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 154 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 155 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 156 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 157 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    • TABLE 158 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 159 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS
  • 11.4 MARKET SHARE ANALYSIS
    • TABLE 160 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 39 COMPANY EVALUATION QUADRANT: THERAPEUTIC DRUG MONITORING MARKET, 2021
  • 11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 40 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: THERAPEUTIC DRUG MONITORING MARKET, 2021
  • 11.7 COMPANY FOOTPRINT ANALYSIS
    • TABLE 161 COMPANY FOOTPRINT
    • TABLE 162 COMPANY REGIONAL FOOTPRINT
    • TABLE 163 COMPANY PRODUCT FOOTPRINT
  • 11.8 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 164 KEY PRODUCT LAUNCHES & APPROVALS
    • 11.9.2 DEALS
    • TABLE 165 KEY DEALS
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 166 KEY OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ABBOTT
    • TABLE 167 ABBOTT: BUSINESS OVERVIEW
    • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2021)
    • 12.1.2 THERMO FISHER SCIENTIFIC
    • TABLE 168 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 12.1.3 F. HOFFMANN-LA ROCHE
    • TABLE 169 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
    • FIGURE 43 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
    • 12.1.4 SIEMENS HEALTHINEERS AG
    • TABLE 170 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
    • FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
    • 12.1.5 DANAHER CORPORATION
    • TABLE 171 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.6 BIO-RAD LABORATORIES
    • TABLE 172 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
    • 12.1.7 BIOMERIEUX SA
    • TABLE 173 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 47 BIOMERIEUX: COMPANY SNAPSHOT (2021)
    • 12.1.8 THERADIAG
    • TABLE 174 THERADIAG: BUSINESS OVERVIEW
    • FIGURE 48 THERADIAG: COMPANY SNAPSHOT (2021)
    • 12.1.9 GRIFOLS S.A.
    • TABLE 175 GRIFOLS S.A.: BUSINESS OVERVIEW
    • FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
    • 12.1.10 EXAGEN INC.
    • TABLE 176 EXAGEN INC.: BUSINESS OVERVIEW
    • FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2021)
    • 12.1.11 ARK DIAGNOSTICS, INC.
    • TABLE 177 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW
    • 12.1.12 R-BIOPHARM AG
    • TABLE 178 R-BIOPHARM AG: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 APDIA GROUP
    • 12.2.2 BIOTEZ BERLIN BUCH GMBH
    • 12.2.3 EAGLE BIOSCIENCES, INC.
    • 12.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
    • 12.2.5 AALTO SCIENTIFIC, LTD.
    • 12.2.6 IMMUNDIAGNOSTIK AG
    • 12.2.7 UTAK
    • 12.2.8 SEKISUI MEDICAL CO., LTD.
    • 12.2.9 DIASYSTEM SCANDINAVIA AB
    • 12.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
    • 12.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
    • 12.2.12 BUHLMANN LABORATORIES AG
    • 12.2.13 SJK GLOBAL, LLC.
    • 12.2.14 EPITOPE DIAGNOSTICS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 CUSTOMIZATION OPTIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS